Current approaches of neoadjuvant chemotherapy in cervical cancer

Expert Review of Anticancer Therapy

Volumn 2, Issue 1, 2002, Pages 73-82

  Aoki, Yoichi ^a   Tanaka, Kenichi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

5 Fluorouracil; Cervical cancer; Cisplatin; Concurrent chemoradiation; Hydroxyurea; Neoadjuvant chemotherapy; Paclitaxel; Radical hysterectomy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CD44V ANTIGEN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; HYDROXYUREA; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PEPLEOMYCIN; PLATINUM DERIVATIVE; PROTEIN P53; TUMOR ANTIGEN; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; RADICAL HYSTERECTOMY; REVIEW; UTERINE CERVIX CANCER;

EID: 0036086971     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.1.73     Document Type: Review

References (56)

1. Global Cancer Statistics
2. Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)
3. Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical uterine squamous-cell carcinoma
4. Induction chemotherapy and radiotherapy of advanced cancer of the cervix: A pilot study and Phase III randomized trial
5. Combined chemotherapy and radiation therapy for advanced carcinoma of the cervix
6. Neoadjuvant therapy for advanced squamous cell carcinoma of the cervix: Cisplatin followed by radiation therapy - A pilot study of the Gynecologic Oncology Group
7. Combined chemotherapy and radiotherapy in patients with advanced squamous carcinoma of the cervix (cis-platinum-bleomycin-vinblastine)
8. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix
9. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer
10. Phase II trial of mitomycin, vincristine, bleomycin and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma
11. Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer
12. Neoadjuvant chemotherapy (CT) + radiaotherapy vs. radiotherapy alone in stage IIIB cervical carcinoma. Preliminary results
13. Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: A randomized study
14. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A
15. Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma
16. Can the published data tell us about the effectiveness of neoadjuvant chemotherapy for locally advanced cancer of the uterine cervix?
17. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: The final results
18. A possible new trend in the management of the carcinoma of the cervix uteri
19. Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
20. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer
21. Neoadjuvant chemotherapy using low-dose consecutive intra-arterial infusion of cisplatin combined with 5-FU for locally advanced cervical adenocarcinoma
22. Neoadjuvant chemotherapy for patients younger than 50 years with high-risk squamous cell carcinoma of the cervix
23. Neoadjuvant chemotherapy (NACT) and radical surgery (RS) vs. exclusive radiotherapy (RT) in locally advanced squamous cell cervical cancer (LASCCC)
24. Phase III randomized study of MVC intra-arterial (arm 1), or systemic (arm 2) neoadjuvant chemotherapy versus radiation therapy only (arm 3) for stage IIb bulky carcinoma of uterine cervix: Preliminary report
25. The role of neoadjuvant intra-arterial infusion chemotherapy with cisplatin and bleomycin for locally advanced cervical cancer
26. High-risk group in node-positive patients with stage IB, IIA and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation
27. Age as a prognostic factor in patients with squamous cell carcinoma of the uterine cervix
28. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
29. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
30. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
31. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Oncology Group study
32. Cisplatin, 5-fluorouracil, plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy
33. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis
34. Stage Ib adenocarcinoma of the cervix: Metastatic potential and patterns of dissemination
35. Neoadjuvant chemotherapy with mitomycin C, etoposide and cisplatin for adenocarcinoma of the cervix
36. Adenocarcinoma of the uterine cervix
37. Prognostic factors of primary adenocarcinoma of the uterine cervix
38. Ovarian metastasis in stage IB and II cervical adenocarcinoma
39. Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma
40. Decrease in tumor volume and histologic response to intraarterial neoadjuvant chemotherapy in patients with cervical and endometrial adenocarcinoma
41. Combination of consecutive low-dose cisplatin with bleomycin, vincristine and mitomycin for recurrent cervical carcinoma
42. Multidisciplinary, intra-arterial chemotherapy (IAC) with CDDP and 5-FU against cervical cancer
43. Combination chemotherapy for metastatic or recurrent adenocarcinoma of the cervix
44. Locally advanced cervical adenocarcinoma: Is there a place for chemosurgical treatment?
45. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma
46. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study
47. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix
48. Effect of cisplatin resistance on cellular radiation response
49. Squamous cell carcinoma antigen: Prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer
50. Multiple tumour marker assays in advanced cervical cancer: Relationship to chemotherapy response and clinical outcome
51. Relationship between squamous cell carcinoma antigen levels and tumor volumes in patients with cervical carcinomas undergoing neoadjuvant chemotherapy
52. Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy
53. Decrease in tumor volume and histologic response to intra-arterial neoadjuvant chemotherapy in patients with cervical and endometrial adenocarcinoma
54. Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-π in the tumor cells of cervical carcinoma
55. NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical - Cancer
56. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma